US advisory panellists on drug's safety had ties to manufacturers.
作者信息
Lenzer Jeanne, Epstein Keith
出版信息
BMJ. 2012 Jan 10;344:e244. doi: 10.1136/bmj.e244.
DOI:10.1136/bmj.e244
PMID:22234908
Abstract
摘要
相似文献
1
US advisory panellists on drug's safety had ties to manufacturers.
BMJ. 2012 Jan 10;344:e244. doi: 10.1136/bmj.e244.
2
Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
MedGenMed. 2006 Oct 30;8(4):22.
3
Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees.
Ann Intern Med. 2016 Oct 18;165(8):606-607. doi: 10.7326/L16-0031.
4
Financial conflicts of interest and the Food and Drug Administration's Advisory Committees.
N Engl J Med. 2005 Jul 14;353(2):116-8. doi: 10.1056/NEJMp058108.
5
Probity gone nuts.
Nat Biotechnol. 2007 May;25(5):483. doi: 10.1038/nbt0507-483.
6
Group says FDA, advisory panels show bias toward drug approvals.
Washington Post. 2006 Aug 29:A13.
7
Settling for second best?
Nat Biotechnol. 2007 Jul;25(7):715-6. doi: 10.1038/nbt0707-715.
8
Conflicts cause FDA to review advisory committees.
CMAJ. 2006 Jul 4;175(1):23. doi: 10.1503/cmaj.060636.
9
When is a point of view a conflict of interest?
BMJ. 2016 Nov 23;355:i6194. doi: 10.1136/bmj.i6194.
10
FDA revamps committee conflict-of-interest rules.
J Natl Cancer Inst. 2006 Oct 4;98(19):1354-5. doi: 10.1093/jnci/djj423.
Zotero 插件